Clinical Observation of Mycophenolate Mofetil Capsules in the Treatment of Primary Immune Thrombocytopenia

OBJECTIVE:To observe clinical efficacy and adverse drug reaction of Mycophenolaie mofetil(MMF)capsules in the treatment of primary immune thrombocytopenia.METHODS:20 patients with primary immune thrombocytopenia from Dec.2011 to Feb.2013 were treated with MMF capsules(500 mg,q12h)in department of hematology of a hospital.Therapeutic efficacy and adverse drug reaction were observed.RESULTS:In 14 patients among 20,blood platelet rose again and haemorrhage symptom was relieved after 2-8 weeks(14/20,70%),all the patients' blood platelet maintained at 41×109-81×109L-1,excepted for 1 paitent(recoverd to normal).The drug dosage of the 14 patients whose blood platelet rose again was decreased after 8 weeks of oral administration of MMF capsules,among which the blood platelet of 6 patients was decreased progressively and lower than 20× 109L-12-6 weeks after decreasing the dose of MMF casuples,and then other drug replaced the therapy.The blood platelet of other 8 patients maintained at 35×109-68×109L-1during decreasing the drug dosage.Among 20 patients,the blood platelet of 6 patients who received MMF capsules for 8 weeks didn't returned to normal but lower than 20×109L-1,and then other drug replaced the therapy(6/20,30%).Total effective rate was 70%.No serious adverse drug reaction was observed.CONCLUSIONS:It is safe and effective for MMF capsules in the treatment of primary immune thrombocytopenia.